Sickle Cell Disease
-
Clinical News
Hemanext® Inc. Receives CE Mark Certification For Innovative Red Blood Cell (RBC) Processing & Storage System
Hemanext Inc. announced today it has received a CE Certificate of Conformity for the CE Mark for its Hemanext ONE Red Blood Cell (RBC) Processing and Storage System, allowing the…
أكمل القراءة » -
TIF News (AR)
TIF Presents Its Newly Launched SCD Educational Course for Healthcare Professionals On 9 April
TIF is delighted to announce the organisation of a Virtual Presentation Event of the ‘TIF Sickle Cell Disease Educational Course for Healthcare Professionals’ – an online course providing comprehensive information…
أكمل القراءة » -
TIF News (AR)
Time To Get Ready For Rare Disease Day 2021!
TIF joins forces with 300 million people around the world for the global observance of Rare Disease Day, coming up on February 28th. Rare Disease Day is an annual awareness…
أكمل القراءة » -
TIF News (AR)
TIF’s Public Statement on Current Developments in Gene Therapy SCD Clinical Trials and Thalassaemia Gene Therapy Zynteglo
The Thalassaemia International Federation (TIF) has been informed through official communication by both the European Medicines Agency (EMA) and bluebird bio that the latter has placed Phase 1/2 and Phase…
أكمل القراءة » -
أخبار
EMA Accepts MAA For Oxbryta To Treat Haemolytic Anaemia In Sickle Cell Disease
The European Medicines Agency (EMA) has accepted Global Blood Therapeutics (GBT) marketing authorisation application (MAA) for Oxbryta® (voxelotor) for the treatment of haemolytic anaemia in sickle cell disease (SCD). According to the company,…
أكمل القراءة » -
Clinical News
Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy
The U.S. Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for the experimental gene editing therapy GPH101 by Graphite Bio to initiate a Phase 1/2…
أكمل القراءة » -
أخبار
THALIA App: The Skilled Digital Assistant of People with Thalassaemia and Sickle Cell Disease
Committed to continuing efforts to develop useful tools for individuals with thalassaemia and haemoglobin disorders worldwide, TIF introduces a novel mobile health application for patients with thalassaemia and sickle cell…
أكمل القراءة » -
أخبار
TIF European Thalassaemia & Sickle Cell Disease Symposium To Take Place On 11-13 December 2020
TIF is proudly organising the European Thalassaemia & Sickle Cell Disease Symposium, a joint patients’ and healthcare professionals’ three-day educational event which will take place online on 11 – 13 December…
أكمل القراءة » -
أخبار
What’s New In Clinical Trials for Thalassaemia and Sickle Cell Disease?
There is a lot of hustle and bustle in the scientific fields of thalassemia and sickle cell disease during the past few months, with many companies making remarkable progress in…
أكمل القراءة » -
أخبار
EU Approves Adakveo to Treat Vaso Occlusive Crises in Sickle Cell Disease Patients
The European Commission has approved Novartis’ Adakveo (crizanlizumab) as a preventive treatment for recurrent Vaso-Occlusive Crises (VOCs) in patients, 16 and older, with sickle cell disease (SCD). This approval follows a recommendation for conditional approval issued in July…
أكمل القراءة »